Total
0
Shares
AusCann Group Holdings (ASX:AC8) - CEO, Layton Mills
CEO, Layton Mills
Source: Business News Australia
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AusCann (AC8) has submitted its first module of DermaCann to the Australian Pesticides and Veterinary Medicines Association (APVMA) to support dogs with dermatological conditions
  • AusCann is aiming for its DermaCann product to become a world-first oral cannabinoid product for skin health in dogs
  • If approved, it would be the first APVMA medicine containing cannabinoids to be supplied via prescription through Australian veterinarians
  • The Australian submission complements the previous submission in South Africa and commercialisation plans in the US
  • Auscann is up 4.76 per cent, trading at 11 cents per share at 1:17 pm AEST

AusCann Group Holdings (AC8) has commenced its Australian product registration for DermaCann.

The company has submitted its first module to the Australian Pesticides and Veterinary Medicines Association (APVMA) to support dogs with dermatological conditions.

AusCann is aiming for its DermaCann product to become a world-first oral cannabinoid product for skin health in dogs. If approved, it would be the first APVMA medicine containing cannabinoids to be supplied via prescription through Australian veterinarians.

There are around one million dogs in Australia who suffer from dermatological conditions, and the global canine skin and dermatitis market is worth an estimated US$1.5 billion (about A$20 billion) globally.

The Australian submission complements the previous submission in South Africa and commercialisation plans in the US.

Last year, DermaCann was shown to be safe and effective at reducing inflammatory skin lesions in dogs diagnosed with atopic dermatitis.

CEO Layton Mills is looking forward to bringing this product to Australian vets.

“Commencing the formal registration pathway with APVMA is consistent
with AusCann’s objective of bringing safe, clinically developed and tested medicines for human and animal health to meet patients’ unmet health needs,” he said.

“We look forward to bringing this world-first product to veterinarians in Australia and other global markets.”

Auscann was up 4.76 per cent, trading at 11 cents per share at 1:17 pm AEST.

AC8 by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).